@Grainger: (Post top of page) From the same site you linked to on the same day a few hours later (all very confusing lol):
"Gilead's Remdesivir Might Be As Good As It Gets"
"Drugs (mostly not yet developed) addressing immune system over-reaction for late stage acute disease might have a role. Mesoblast Remestemcel-L is possible but probably too expensive."
"Another company investigating COVID-ARDS is Mesoblast (MESO) which has a mesenchymal stem cell product, remestemcel-L, which is being trialed for end stage COVID-19, where the fatality rate is extremely high. Remestemcel-L is a very high cost live cell product which, even if it works, would have a limited market because of the very high cost."
https://seekingalpha.com/article/4352097-covidminus-19-gileads-remdesivir-might-be-good-gets?app=1&utm_medium=email&utm_source=seeking_alpha&mail_subject=pre-market-summary-on-your-portfolio-portfolio-1&utm_campaign=nl-portfolio&utm_content=link-4
Seems things are hotting up.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-3226
-
-
- There are more pages in this discussion • 15,023 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B |
Open | High | Low | Value | Volume |
$1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 59739 | $1.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.36 | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 59739 | 1.350 |
4 | 14088 | 1.345 |
2 | 47555 | 1.340 |
3 | 94633 | 1.335 |
4 | 66925 | 1.330 |
Price($) | Vol. | No. |
---|---|---|
1.360 | 5000 | 1 |
1.365 | 56441 | 4 |
1.370 | 140305 | 9 |
1.375 | 37954 | 3 |
1.380 | 113521 | 16 |
Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |